Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 598
Filter
1.
Drug Dev Res ; 85(3): e22194, 2024 May.
Article in English | MEDLINE | ID: mdl-38704828

ABSTRACT

The aim the present study was to investigate the impact of novel pentavalent organobismuth and organoantimony complexes on membrane integrity and their interaction with DNA, activity against Sb(III)-sensitive and -resistant Leishmania strains and toxicity in mammalian peritoneal macrophages. Ph3M(L)2 type complexes were synthesized, where M = Sb(V) or Bi(V) and L = deprotonated 3-(dimethylamino)benzoic acid or 2-acetylbenzoic acid. Both organobismuth(V) and organoantimony(V) complexes exhibited efficacy at micromolar concentrations against Leishmania amazonensis and L. infantum but only the later ones demonstrated biocompatibility. Ph3Sb(L1)2 and Ph3Bi(L1)2 demonstrated distinct susceptibility profiles compared to inorganic Sb(III)-resistant strains of MRPA-overexpressing L. amazonensis and AQP1-mutated L. guyanensis. These complexes were able to permeate the cell membrane and interact with the Leishmania DNA, suggesting that this effect may contribute to the parasite growth inhibition via apoptosis. Taken altogether, our data substantiate the notion of a distinct mechanism of uptake pathway and action in Leishmania for these organometallic complexes, distinguishing them from the conventional inorganic antimonial drugs.


Subject(s)
Antimony , Antiprotozoal Agents , Cell Membrane , Drug Resistance , Organometallic Compounds , Antimony/pharmacology , Antimony/chemistry , Animals , Organometallic Compounds/pharmacology , Mice , Cell Membrane/drug effects , Antiprotozoal Agents/pharmacology , Macrophages, Peritoneal/drug effects , Macrophages, Peritoneal/parasitology , Leishmania/drug effects , DNA, Protozoan , Leishmania infantum/drug effects , Leishmania infantum/genetics , Mice, Inbred BALB C
2.
Parasitology ; 151(5): 506-513, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38533610

ABSTRACT

Leishmania is a trypanosomatid parasite that causes skin lesions in its cutaneous form. Current therapies rely on old and expensive drugs, against which the parasites have acquired considerable resistance. Trypanosomatids are unable to synthesize purines relying on salvaging from the host, and nucleoside analogues have emerged as attractive antiparasitic drug candidates. 4-Methyl-7-ß-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidine (CL5564), an analogue of tubercidin in which the amine has been replaced by a methyl group, demonstrates activity against Trypanosoma cruzi and Leishmania infantum. Herein, we investigated its in vitro and in vivo activity against L. amazonensis. CL5564 was 6.5-fold (P = 0.0002) more potent than milteforan™ (ML) against intracellular forms in peritoneal mouse macrophages, and highly selective, while combination with ML gave an additive effect. These results stimulated us to study the activity of CL5564 in mouse model of cutaneous Leishmania infection. BALB/c female and male mice infected by L. amazonensis treated with CL5564 (10 mg kg−1, intralesional route for five days) presented a >93% reduction of paw lesion size likely ML given orally at 40 mg kg−1, while the combination (10 + 40 mg kg−1 of CL5564 and ML, respectively) caused >96% reduction. The qPCR confirmed the suppression of parasite load, but only the combination approach reached 66% of parasitological cure. These results support additional studies with nucleoside derivatives.


Subject(s)
Disease Models, Animal , Leishmania mexicana , Leishmaniasis, Cutaneous , Mice, Inbred BALB C , Animals , Leishmaniasis, Cutaneous/drug therapy , Leishmaniasis, Cutaneous/parasitology , Mice , Female , Male , Leishmania mexicana/drug effects , Tubercidin/pharmacology , Tubercidin/analogs & derivatives , Antiprotozoal Agents/pharmacology , Antiprotozoal Agents/therapeutic use , Antiprotozoal Agents/administration & dosage , Macrophages, Peritoneal/parasitology , Macrophages, Peritoneal/drug effects , Leishmania/drug effects
3.
J Basic Microbiol ; 64(5): e2300490, 2024 May.
Article in English | MEDLINE | ID: mdl-38227394

ABSTRACT

Currently, zinc oxide (ZnO) particles are used in nanotechnology to destroy a wide range of microorganisms. Although pentavalent antimony compounds are used as antileishmanial drugs, they are associated with several limitations and side effects. Therefore, it is always desirable to try to find new and effective treatments. The aim of this research is to determine the antileishmanial effect of ZnO particles in comparison to the Antimoan Meglumine compound on promastigotes and amastigotes of Leishmania major (MRHO/IR/75/ER). After the extraction and purification of macrophages from the peritoneal cavity of C57BL/6 mice, L. major parasites were cultured in Roswell Park Memorial Institute-1640 culture medium containing fetal bovine serum (FBS) 10% and antibiotic. In this experimental study, the effect of different concentrations of nanoparticles was investigated using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) colorimetric method, in comparison to the glucantime on promastigotes, amastigotes and healthy macrophages in the culture medium. The amount of light absorption of the obtained color from the regeneration of tetrazolium salt to the product color of formazan by the parasite was measured by an enzyme-linked immunosorbent assay (ELISA) reader, and the IC50 value was calculated. IC50 after 24 h of incubation was calculated as IC50 = 358.6 µg/mL. The results showed, that the efficacy of ZnO nanoparticles was favorable and dose-dependent. The concentration of 500 µg/mL of ZnO nanoparticles induced 84.67% apoptosis after 72. Also, the toxicity of nanoparticles was less than the drug. Nanoparticles exert their cytotoxic effects by inducing apoptosis. They can be suitable candidates in the pharmaceutical industry in the future.


Subject(s)
Antiprotozoal Agents , Leishmania major , Meglumine Antimoniate , Zinc Oxide , Zinc Oxide/pharmacology , Zinc Oxide/chemistry , Animals , Leishmania major/drug effects , Mice , Antiprotozoal Agents/pharmacology , Meglumine Antimoniate/pharmacology , Mice, Inbred C57BL , Nanoparticles/chemistry , Macrophages/parasitology , Macrophages/drug effects , Inhibitory Concentration 50 , Macrophages, Peritoneal/parasitology , Macrophages, Peritoneal/drug effects , Metal Nanoparticles/chemistry
4.
Front Cell Infect Microbiol ; 12: 882555, 2022.
Article in English | MEDLINE | ID: mdl-35601101

ABSTRACT

Chagas disease (CD), caused by the hemoflagellate protozoan Trypanosoma cruzi, affects more than six million people worldwide and presents an unsatisfactory therapy, based on two nitroderivatives, introduced in clinical medicine for decades. The synthetic peptide, with CTHRSSVVC sequence (PepA), mimics the CD163 and TNF-α tripeptide "RSS" motif and binds to atheromatous plaques in carotid biopsies of human patients, spleen tissues, and a low-density lipoprotein receptor knockout (LDLr-/-) mouse model of atherosclerosis. CD163 receptor is present on monocytes, macrophages, and neutrophils, acting as a regulator of acute-phase processes and modulating aspects of the inflammatory response and the establishment of infections. Due to the potential theranostic role of PepA, our aim was to investigate its effect upon T. cruzi infection in vitro and in vivo. PepA and two other peptides with shuffled sequences were assayed upon different binomials of host cell/parasite, including professional [as peritoneal mouse macrophages (PMM)] and non-professional phagocytes [primary cultures of cardiac cells (CM)], under different protocols. Also, their impact was further addressed in vivo using a mouse model of acute experimental Chagas disease. Our in-vitro findings demonstrate that PepA and PepB (the peptide with random sequence retaining the "RS" sequence) reduced the intracellular parasitism of the PMM but were inactive during the infection of cardiac cells. Another set of in-vitro and in-vivo studies showed that they do not display a trypanocidal effect on bloodstream trypomastigotes nor exhibit in-vivo efficacy when administered after the parasite inoculation. Our data report the in-vitro activity of PepA and PepB upon the infection of PMM by T. cruzi, possibly triggering the microbicidal arsenal of the host professional phagocytes, capable of controlling parasitic invasion and proliferation.


Subject(s)
Chagas Disease , Trypanosoma cruzi , Chagas Disease/parasitology , Humans , Macrophages, Peritoneal/parasitology , Models, Theoretical , Peptides/metabolism , Peptides/pharmacology , Trypanosoma cruzi/metabolism
5.
Biomed Res Int ; 2022: 9928362, 2022.
Article in English | MEDLINE | ID: mdl-35187176

ABSTRACT

Endogenous nucleotides produced by various group of cells under inflammatory conditions act as potential danger signals in vivo. Extracellularly released nucleotides such as ATP are rapidly hydrolyzed to adenosine by the coordinated ectonucleotidase activities of CD39 and CD73. Leishmania is an obligate intracellular parasite of macrophages and capable of modulating host immune response in order to survive and multiply within host cells. In this study, the activity of CD73 induced by Leishmania amazonensis in infected macrophages has been investigated and correlated with parasite survival and infection in vitro. For this, the expression of CD39 and CD73, by flow cytometry, in murine peritoneal macrophages infected with metacyclic promastigotes of L. amazonensis has been analyzed. Our results showed that L. amazonensis-infected macrophages, unlike LPS-treated macrophages, increased CD73 expression. It was also noted that when CD73 enzymatic activity was blocked by α, ß-methyleneadenosine 5'-diphosphate sodium salt (APCP), macrophage parasitism was significantly decreased. Interestingly, these effects were not associated with the production of TNF-α, IL-10, or nitric oxide (NO). Together, these data demonstrate that L. amazonensis induces a regulatory phenotype in macrophages, which by activating the CD39/CD73 pathway allows parasite survival through the action of immunomodulatory adenosine receptors.


Subject(s)
5'-Nucleotidase/metabolism , Adenosine Triphosphatases/metabolism , Leishmania mexicana/enzymology , Macrophages, Peritoneal/parasitology , Animals , Antigens, CD/metabolism , Apyrase/metabolism , Mice , Mice, Inbred C57BL
6.
PLoS One ; 16(11): e0259008, 2021.
Article in English | MEDLINE | ID: mdl-34723989

ABSTRACT

Leishmaniasis is a neglected disease that affects 12 million people living mainly in developing countries. Herein, 24 new N-oxide-containing compounds were synthesized followed by in vitro and in vivo evaluation of their antileishmanial activity. Compound 4f, a furoxan derivative, was particularly remarkable in this regard, with EC50 value of 3.6 µM against L. infantum amastigote forms and CC50 value superior to 500 µM against murine peritoneal macrophages. In vitro studies suggested that 4f may act by a dual effect, by releasing nitric oxide after biotransformation and by inhibiting cysteine protease CPB (IC50: 4.5 µM). In vivo studies using an acute model of infection showed that compound 4f at 7.7 mg/Kg reduced ~90% of parasite burden in the liver and spleen of L. infantum-infected BALB/c mice. Altogether, these outcomes highlight furoxan 4f as a promising compound for further evaluation as an antileishmanial agent.


Subject(s)
Antiprotozoal Agents/pharmacology , Drug Design , Leishmania infantum/drug effects , Oxides/pharmacology , Animals , Antiprotozoal Agents/chemical synthesis , Antiprotozoal Agents/chemistry , Biomarkers/metabolism , Carbon-13 Magnetic Resonance Spectroscopy , Ligands , Macrophages, Peritoneal/drug effects , Macrophages, Peritoneal/parasitology , Male , Mice , Molecular Docking Simulation , Nitric Oxide/analysis , Nitrites/analysis , Oxadiazoles/chemical synthesis , Oxadiazoles/chemistry , Oxides/chemical synthesis , Oxides/chemistry , Parasite Load , Pichia/metabolism , Proton Magnetic Resonance Spectroscopy , Protozoan Proteins/metabolism
7.
J Med Chem ; 64(17): 12691-12704, 2021 09 09.
Article in English | MEDLINE | ID: mdl-34427442

ABSTRACT

1,2,3-Triazole is one of the most flexible chemical scaffolds broadly used in various fields. Here, we report the antileishmanial activity of 1,2,3-triazole derivatives, the ultrastructural alterations induced by their treatment, and the nitric oxide (NO) modulation effect on their efficacy against Leishmania amazonensis in vitro infection. After the screening of eleven compounds, compound 4 exhibited better results against L. amazonensis promastigotes (IC50 = 15.52 ± 3.782 µM) and intracellular amastigotes (IC50 = 4.10 ± 1.136 µM), 50% cytotoxicity concentration at 84.01 ± 3.064 µM against BALB/c peritoneal macrophages, and 20.49-fold selectivity for the parasite over the cells. Compound 4 induced ultrastructural mitochondrial alterations and lipid inclusions in L. amazonensis promastigotes, upregulated tumor necrosis factor α, interleukin (IL)-1ß, IL-6, IL-12, and IL-10 messenger RNA expressions, and enhanced the NO production, verified by nitrite (p = 0.0095) and inducible nitric oxide synthase expression (p = 0.0049) quantification, which played an important role in its activity against intramacrophagic L. amazonensis. In silico prediction in association with antileishmanial activity results showed compound 4 as a hit compound with promising potential for further studies of new leishmaniasis treatment options.


Subject(s)
Antiprotozoal Agents/pharmacology , Leishmania/drug effects , Macrophages, Peritoneal/drug effects , Macrophages, Peritoneal/parasitology , Nitric Oxide/metabolism , Triazoles/pharmacology , Animals , Antiprotozoal Agents/chemistry , Cell Line , Cell Survival/drug effects , Female , Fibroblasts/drug effects , Fibroblasts/parasitology , Gene Expression Regulation, Enzymologic/drug effects , Humans , Mice , Mice, Inbred BALB C , Molecular Structure , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/metabolism , Triazoles/chemistry
8.
Exp Parasitol ; 229: 108152, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34419413

ABSTRACT

Dog roundworm (Toxocara canis) is the major causative agent of toxocarosis, a parasitic disease of both veterinary and medical importance. Knowledge gaps in fundamental and applied aspects hinder the control of this important zoonotic disease. To have a better understanding of Toxocara infection and host immune responses, mouse macrophages were exposed to excretory/secretory (ES) proteins released by adult worms of T. canis in vitro. The messenger RNA transcription and protein expression of nucleotide-binding oligomerization domain-containing protein 1 (NOD1), receptor interacting protein 2 (RIP2) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) in macrophages were analysed using quantitative real-time PCR (qRT-PCR) and Western blot. The levels of tumour necrosis factor alpha (TNF-ɑ), interleukin-1 beta (IL-1ß) and IL-6 released by the stimulated macrophages were analysed using enzyme-linked immunosorbent assay. It was found that 20 µg/mL ES proteins of adult T. canis induced the expression of NOD1, RIP2 and NF-κB in mouse macrophages at both transcriptional and translational levels after 9 h of incubation in vitro. Incubation with 20 µg/mL ES proteins also modulated the production of pro-inflammatory cytokines TNF-ɑ, IL-1ß and IL-6 by the macrophages. Taken together, ES proteins of adult T. canis appeared to be able to affect the macrophage NOD1-RIP2-NF-κB signalling pathway, which might play a role in regulating the production of proinflammatory cytokines. Further investigation of these aspects should lead to a better understanding of immune recognition of and modulation by Toxocara canis in host animals.


Subject(s)
Cytokines/biosynthesis , Helminth Proteins/metabolism , Macrophages, Peritoneal/metabolism , Toxocara canis/metabolism , Animals , Blotting, Western , Cell Survival , Cytokines/metabolism , Dogs , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Female , Helminth Proteins/pharmacology , Interleukin-1beta/biosynthesis , Interleukin-1beta/metabolism , Interleukin-6/biosynthesis , Interleukin-6/metabolism , Macrophages, Peritoneal/drug effects , Macrophages, Peritoneal/parasitology , Mice , Mice, Inbred C57BL , NF-kappa B/metabolism , Nod1 Signaling Adaptor Protein/metabolism , Receptor-Interacting Protein Serine-Threonine Kinase 2/metabolism , Toxocara canis/chemistry , Tumor Necrosis Factor-alpha/biosynthesis , Tumor Necrosis Factor-alpha/metabolism
9.
J Immunol ; 207(6): 1507-1512, 2021 09 15.
Article in English | MEDLINE | ID: mdl-34400524

ABSTRACT

Resistance and tolerance are vital for survivability of the host-pathogen relationship. Virulence during Toxoplasma infection in mice is mediated by parasite kinase-dependent antagonism of IFN-γ-induced host resistance. Whether avirulence requires expression of parasite factors that induce host tolerance mechanisms or is a default status reflecting the absence of resistance-interfering factors is not known. In this study, we present evidence that avirulence in Toxoplasma requires parasite engagement of the scavenger receptor CD36. CD36 promotes macrophage tropism but is dispensable for the development of resistance mechanisms. Instead CD36 is critical for re-establishing tissue homeostasis and survival following the acute phase of infection. The CD36-binding capacity of T. gondii strains is negatively controlled by the virulence factor, ROP18. Thus, the absence of resistance-interfering virulence factors and the presence of tolerance-inducing avirulence factors are both required for long-term host-pathogen survival.


Subject(s)
CD36 Antigens/deficiency , CD36 Antigens/metabolism , Macrophages, Peritoneal/immunology , Macrophages, Peritoneal/parasitology , Toxoplasma/metabolism , Toxoplasma/pathogenicity , Toxoplasmosis, Animal/immunology , Animals , CD36 Antigens/genetics , CHO Cells , Cricetulus , Host-Pathogen Interactions/genetics , Host-Pathogen Interactions/immunology , Immune Tolerance/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Protein Serine-Threonine Kinases/metabolism , Protozoan Proteins/metabolism , RAW 264.7 Cells , Toxoplasmosis, Animal/metabolism , Toxoplasmosis, Animal/parasitology , Virulence/genetics , Virulence Factors/metabolism
10.
Cell Death Dis ; 12(7): 692, 2021 07 10.
Article in English | MEDLINE | ID: mdl-34247195

ABSTRACT

Chagas disease is a life-threatening disorder caused by the protozoan parasite Trypanosoma cruzi. Parasite-specific antibodies, CD8+ T cells, as well as IFN-γ and nitric oxide (NO) are key elements of the adaptive and innate immunity against the extracellular and intracellular forms of the parasite. Bim is a potent pro-apoptotic member of the Bcl-2 family implicated in different aspects of the immune regulation, such as negative selection of self-reactive thymocytes and elimination of antigen-specific T cells at the end of an immune response. Interestingly, the role of Bim during infections remains largely unidentified. To explore the role of Bim in Chagas disease, we infected WT, Bim+/-, Bim-/- mice with trypomastigotes forms of the Y strain of T. cruzi. Strikingly, our data revealed that Bim-/- mice exhibit a delay in the development of parasitemia followed by a deficiency in the control of parasite load in the bloodstream and a decreased survival compared to WT and Bim+/- mice. At the peak of parasitemia, peritoneal macrophages of Bim-/- mice exhibit decreased NO production, which correlated with a decrease in the pro-inflammatory Small Peritoneal Macrophage (SPM) subset. A similar reduction in NO secretion, as well as in the pro-inflammatory cytokines IFN-γ and IL-6, was also observed in Bim-/- splenocytes. Moreover, an impaired anti-T. cruzi CD8+ T-cell response was found in Bim-/- mice at this time point. Taken together, our results suggest that these alterations may contribute to the establishment of a delayed yet enlarged parasitic load observed at day 9 after infection of Bim-/- mice and place Bim as an important protein in the control of T. cruzi infections.


Subject(s)
Bcl-2-Like Protein 11/deficiency , Chagas Disease/parasitology , Trypanosoma cruzi/pathogenicity , Animals , Bcl-2-Like Protein 11/genetics , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/parasitology , Cells, Cultured , Chagas Disease/genetics , Chagas Disease/immunology , Chagas Disease/metabolism , Disease Models, Animal , Female , Host-Parasite Interactions , Interferon-gamma/metabolism , Interleukin-6/metabolism , Macrophages, Peritoneal/immunology , Macrophages, Peritoneal/metabolism , Macrophages, Peritoneal/parasitology , Mice, Inbred C57BL , Mice, Knockout , Nitric Oxide/metabolism , Parasite Load , Spleen/immunology , Spleen/metabolism , Spleen/parasitology , Time Factors , Trypanosoma cruzi/immunology
11.
Molecules ; 26(11)2021 Jun 02.
Article in English | MEDLINE | ID: mdl-34199336

ABSTRACT

The natural compound ravenelin was isolated from the biomass extracts of Exserohilum rostratum fungus, and its antimicrobial, antiplasmodial, and trypanocidal activities were evaluated. Ravenelin was isolated by column chromatography and HPLC and identified by NMR and MS. The susceptibility of Gram-positive and Gram-negative bacteria strains to ravenelin was determined by microbroth dilution assay. Cytotoxicity was evaluated in hepatocarcinoma cells (HepG2) and BALB/c peritoneal macrophages by using MTT. SYBR Green I-based assay was used in the asexual stages of Plasmodium falciparum. Trypanocidal activity was tested against the epimastigote and intracellular amastigote forms of Trypanosoma cruzi. Ravenelin was active against Gram-positive bacteria strains, with emphasis on Bacillus subtilis (MIC value of 7.5 µM). Ravenelin's antiparasitic activities were assessed against both the epimastigote (IC50 value of 5 ± 1 µM) and the intracellular amastigote forms of T. cruzi (IC50 value of 9 ± 2 µM), as well as against P. falciparum (IC50 value of 3.4 ± 0.4 µM). Ravenelin showed low cytotoxic effects on both HepG2 (CC50 > 50 µM) and peritoneal macrophage (CC50 = 185 ± 1 µM) cells with attractive selectivity for the parasites (SI values > 15). These findings indicate that ravenelin is a natural compound with both antibacterial and antiparasitic activities, and considerable selectivity indexes. Therefore, ravenelin is an attractive candidate for hit-to-lead development.


Subject(s)
Anti-Bacterial Agents/pharmacology , Antiprotozoal Agents/pharmacology , Ascomycota/chemistry , Macrophages, Peritoneal/cytology , Xanthones/pharmacology , Animals , Anti-Bacterial Agents/chemistry , Antiprotozoal Agents/chemistry , Biological Products/chemistry , Biological Products/pharmacology , Biomass , Cell Proliferation/drug effects , Cell Survival/drug effects , Cells, Cultured , Chromatography, High Pressure Liquid , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Hep G2 Cells , Humans , Macrophages, Peritoneal/drug effects , Macrophages, Peritoneal/parasitology , Magnetic Resonance Spectroscopy , Mice , Mice, Inbred BALB C , Microbial Sensitivity Tests , Molecular Structure , Plasmodium falciparum/drug effects , Trypanosoma cruzi/drug effects , Xanthones/chemistry
12.
PLoS Negl Trop Dis ; 15(7): e0009613, 2021 07.
Article in English | MEDLINE | ID: mdl-34314435

ABSTRACT

Chagas disease, caused by the parasite Trypanosoma cruzi, is considered endemic in more than 20 countries but lacks both an approved vaccine and limited treatment for its chronic stage. Chronic infection is most harmful to human health because of long-term parasitic infection of the heart. Here we show that immunization with a virus-like particle vaccine displaying a high density of the immunogenic α-Gal trisaccharide (Qß-αGal) induced several beneficial effects concerning acute and chronic T. cruzi infection in α1,3-galactosyltransferase knockout mice. Approximately 60% of these animals were protected from initial infection with high parasite loads. Vaccinated animals also produced high anti-αGal IgG antibody titers, improved IFN-γ and IL-12 cytokine production, and controlled parasitemia in the acute phase at 8 days post-infection (dpi) for the Y strain and 22 dpi for the Colombian strain. In the chronic stage of infection (36 and 190 dpi, respectively), all of the vaccinated group survived, showing significantly decreased heart inflammation and clearance of amastigote nests from the heart tissue.


Subject(s)
Chagas Cardiomyopathy/prevention & control , Heart/parasitology , Protozoan Vaccines/immunology , Trypanosoma cruzi , Animals , Antibodies, Protozoan/blood , Chagas Cardiomyopathy/parasitology , Chagas Cardiomyopathy/pathology , Cytokines/genetics , Cytokines/metabolism , Female , Gene Expression Regulation/immunology , Immunoglobulin G/blood , Macrophages, Peritoneal/immunology , Macrophages, Peritoneal/metabolism , Macrophages, Peritoneal/parasitology , Mice , Mice, Inbred C57BL , Parasitemia , Toll-Like Receptor 2/genetics , Toll-Like Receptor 2/metabolism , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/metabolism
13.
J Pharm Pharmacol ; 73(9): 1180-1190, 2021 Aug 12.
Article in English | MEDLINE | ID: mdl-33940589

ABSTRACT

OBJECTIVES: Evaluation of the anti-Leishmanial activity of imidazoquinoline-based TLR7/8 agonists. METHODS: TLR7/8-active imidazoquinolines (2 and 3) were synthesized and assessed for activity against Leishmania amazonensis-intracellular amastigotes using mouse peritoneal macrophages. The production of reactive oxygen species (ROS), nitric oxide (NO) and cytokines was determined in infected and non-infected macrophages. KEY FINDINGS: The imidazoquinolines, 2 and 3, were primarily agonists of TLR7 with compound 3 also showing modest TLR8 activity. Docking studies showed them to occupy the same binding pocket on TLR7 and 8 as the known agonists, imiquimod and resiquimod. Compounds 2 and 3 inhibited the growth of L. amazonensis-intracellular amastigotes with the most potent compound (3, IC50 = 5.93 µM) having an IC50 value close to miltefosine (IC50 = 4.05 µM), a known anti-Leishmanial drug. Compound 3 induced macrophages to produce ROS, NO and inflammatory cytokines that likely explain the anti-Leishmanial effects. CONCLUSIONS: This study shows that activating TLR7 using compounds 2 or 3 induces anti-Leishmanial activity associated with induction of free radicals and inflammatory cytokines able to kill the parasites. While 2 and 3 had a very narrow cytotoxicity window for macrophages, this identifies the possibility to further develop this chemical scaffold to less cytotoxic TLR7/8 agonist for potential use as anti-Leishmanial drug.


Subject(s)
Antiprotozoal Agents/pharmacology , Leishmania/drug effects , Macrophages, Peritoneal/drug effects , Toll-Like Receptor 7/agonists , Toll-Like Receptor 8/agonists , Animals , Antiprotozoal Agents/chemical synthesis , Cytokines/metabolism , Female , Humans , Imidazoles , Imiquimod , Inflammation/metabolism , Leishmaniasis/parasitology , Macrophages, Peritoneal/parasitology , Mice, Inbred BALB C , Nitric Oxide/metabolism , Reactive Oxygen Species/metabolism
14.
J Infect Dev Ctries ; 15(2): 270-279, 2021 03 07.
Article in English | MEDLINE | ID: mdl-33690211

ABSTRACT

INTRODUCTION: Trypanosoma cruzi is the agent of Chagas' disease and affects approximately 6-8 million people worldwide. The search for new anti-T. cruzi drugs are relevant because only two drugs exist actually. The objective of this study was to investigate the effect of the extracts from the seeds of Lonchocarpus cultratus on T. cruzi, its cytotoxicity as well as to elucidate its chemical profile. METHODOLOGY: The characterization of the extracts was done using 1H-RMN. T. cruzi forms were treated with increasing concentrations of the extracts and after, the percentage of inhibition and IC50 or LC50 were calculated. Murine peritoneal macrophages were treated with different concentrations of the extracts to evaluate the cellular viability. The hemotoxicity was accessed by verifying the levels of hemolysis caused by the extracts on human red blood cells. RESULTS: Chalcones isocordoin and lonchocarpin were detected in the dichloromethane extract, and chalcone lonchocarpin was detected in the hexane extract. The dichloromethane extract showed higher activity against all the forms of T. cruzi compared to the other two extracts, but the hexane showed the best selectivity index. The cytotoxicity observed in murine macrophages was confirmed in human erythrocytes, with dichloromethane extract having the highest toxicity. The methanolic extract showed the lowest anti-T. cruzi activity but was nontoxic to peritoneal murine macrophages and red blood cells. CONCLUSIONS: L. cultratus extracts have the potential to be explored for the development of new anti-trypanosomal drugs. This study was the first to demonstrate the action of extracts from the genus Lonchocarpus on infecting forms of T. cruzi.


Subject(s)
Fabaceae/chemistry , Macrophages, Peritoneal/parasitology , Plant Extracts/pharmacology , Seeds/chemistry , Trypanosoma cruzi/drug effects , Animals , Chagas Disease/drug therapy , Fabaceae/classification , Humans , Inhibitory Concentration 50 , Macrophages, Peritoneal/drug effects , Mice , Mice, Inbred BALB C
15.
Mem Inst Oswaldo Cruz ; 116: e200417, 2021.
Article in English | MEDLINE | ID: mdl-33729328

ABSTRACT

BACKGROUND: Toxoplasma gondii causes toxoplasmosis and is controlled by activated macrophages. However, infection of macrophages by tachyzoites induces TGF-ß signaling (TGF-s) inhibiting nitric oxide (NO) production. NO inhibition may be a general escape mechanism of distinct T. gondii strains. OBJECTIVES: To evaluate in activated macrophages the capacity of T. gondii strains of different virulence and genetics (RH, type I; ME-49, type II; VEG, type III; P-Br, recombinant) to evade the NO microbicidal defense system and determine LC3 loading to the parasitophorous vacuole. METHODS: Activated peritoneal macrophages were infected with the different T. gondii strains, NO-production was evaluated by the Griess reagent, and inducible nitric oxide synthase expression, TGF-s, and LC3 localisation assayed by immunofluorescence. FINDINGS: Only RH persisted in macrophages, while VEG was more resistant than P-Br and ME-49. All strains induced TGF-s, degradation of inducible nitric oxide synthase, and NO-production inhibition from 2 to 24 h of infection, but only RH sustained these alterations for 48 h. By 24 h of infection, TGF-s lowered in macrophages infected by ME-49, and P-Br, and NO-production recovered, while VEG sustained TGF-s and NO-production inhibition longer. LC3 loading to parasitophorous vacuole was strain-dependent: higher for ME-49, P-Br and VEG, lower for RH. All strains inhibited NO-production, but only RH sustained this effect probably because it persisted in macrophages due to additional evasive mechanisms as lower LC3 loading to parasitophorous vacuole. MAIN CONCLUSIONS: These results support that T. gondii can escape the NO microbicidal defense system at the initial phase of the infection, but only the virulent strain sustain this evasion mechanism.


Subject(s)
Macrophages, Peritoneal/parasitology , Macrophages/parasitology , Nitric Oxide Synthase/metabolism , Nitric Oxide/biosynthesis , Toxoplasma/physiology , Animals , Macrophages/metabolism , Mice , Toxoplasmosis, Animal/parasitology
16.
PLoS Negl Trop Dis ; 15(2): e0009225, 2021 02.
Article in English | MEDLINE | ID: mdl-33617537

ABSTRACT

Leishmania parasites can trigger different host immune responses that result in varying levels of disease severity. The C57BL/6 and BALB/c mouse strains are among the host models commonly used for characterizing the immunopathogenesis of Leishmania species and the possible antileishmanial effect of novel drug candidates. C57BL/6 mice tend to be resistant to Leishmania infections, whereas BALB/c mice display a susceptible phenotype. Studying species-specific interactions between Leishmania parasites and different host systems is a key step to characterize and validate these models for in vivo studies. Here, we use RNA-Seq and differential expression analysis to characterize the transcriptomic profiles of C57BL/6 and BALB/c peritoneal-derived macrophages in response to Leishmania panamensis infection. We observed differences between BALB/c and C57BL/6 macrophages regarding pathways associated with lysosomal degradation, arginine metabolism and the regulation of cell cycle. We also observed differences in the expression of chemokine and cytokine genes associated with regulation of immune responses. In conclusion, infection with L. panamensis induced an inflammatory gene expression pattern in C57BL/6 macrophages that is more consistently associated with a classic macrophage M1 activation, whereas in BALB/c macrophages a gene expression pattern consistent with an intermediate inflammatory response was observed.


Subject(s)
Leishmaniasis/metabolism , Macrophages, Peritoneal/metabolism , Transcriptome , Animals , Disease Models, Animal , Female , Inflammation Mediators , Leishmania guyanensis/physiology , Leishmaniasis/genetics , Macrophages, Peritoneal/parasitology , Mice, Inbred BALB C , Mice, Inbred C57BL , RNA-Seq
17.
Biomed Pharmacother ; 134: 111120, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33341671

ABSTRACT

Visceral leishmaniasis (VL) is a systemic parasitic disease that leads to high rates of morbidity and mortality in humans worldwide. There is a great need to develop new drugs and novel strategies to make chemotherapy for this disease more efficacious and well tolerated. Recent reports on the immunomodulatory effects and the low toxicity of the spherical carbon nanostructure fullerol led us to investigate in vitro and in vivo antileishmanial activity in free and encapsulated forms in liposomes. When assayed against intramacrophagic Leishmania amastigotes, fullerol showed a dose-dependent reduction of the infection index with IC50 of 0.042 mg/mL. When given daily by i.p. route for 20 days (0.05 mg/kg/d) in a murine model of acute VL, fullerol promoted significant reduction in the liver parasite load. To improve the delivery of fullerol to the infection sites, liposomal formulations were prepared by the dehydration-rehydration method. When evaluated in the acute VL model, liposomal fullerol (Lip-Ful) formulations given i.p. at 0.05 and 0.2 mg/kg with 4-days intervals were more effective than the free form, with significant parasite reductions in both liver and spleen. Lip-Ful at 0.2 mg/kg promoted complete parasite elimination in the liver. The antileishmanial activity of Lip-Ful was further confirmed in a chronic model of VL. Lip-Ful was also found to induce secretion of pro-inflammatory TNF-α, IFN-γ and IL-1ß cytokines. In conclusion, this work reports for the first time the antileishmanial activity of fullerol and introduces an innovative approach for treatment of VL based on the association of this nanostructure with liposomes.


Subject(s)
Fullerenes/pharmacology , Leishmania infantum/drug effects , Leishmania mexicana/drug effects , Leishmaniasis, Visceral/drug therapy , Lipids/chemistry , Liver/parasitology , Macrophages, Peritoneal/parasitology , Trypanocidal Agents/pharmacology , Animals , Cytokines/blood , Disease Models, Animal , Drug Compounding , Female , Fullerenes/chemistry , Inflammation Mediators/blood , Leishmania infantum/growth & development , Leishmania mexicana/growth & development , Leishmaniasis, Visceral/blood , Leishmaniasis, Visceral/parasitology , Liposomes , Liver/metabolism , Mesocricetus , Mice, Inbred BALB C , Nanoparticles , Parasite Load , Trypanocidal Agents/chemistry
18.
Int Immunopharmacol ; 91: 107291, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33360084

ABSTRACT

Present treatment regimen on visceral leishmaniasis has multiple limitations including severe side effects, toxicity, and resistance of Leishmania strains. Amphotericin B is a well-established pharmacologically approved drug; however, mainly toxicity is a foremost issue with that drug. Recently, our group identified eugenol oleate as an anti-leishmanial immunomodulatory compound. The important objectives of this present study was to evaluate the possible synergistic effect of eugenol oleate with amphotericin B to reduce the toxicity of this approved drug. Results obtained from this study signified that combination of eugenol oleate and amphotericin B showed indifferent combinatorial effect against promastigotes with xΣFIC 1.015, while, moderate synergistic activity with xΣFIC 0.456 against amastigotes. It was also notable that eugenol oleate (2.5 µM) with low concentrations of amphotericin B (0.3125 µM) showed 96.45% parasite reduction within L. donovani-infected murine macrophages. Furthermore, eugenol oleate and amphotericin B significantly (p < 0.01) enhanced the nitrite generation, and pro-inflammatory cytokines (IL-12, IFN-γ and TNF-α) in infected macrophages in vitro and in BALB/c mice in vivo. Eugenol oleate (10 mg/Kg b. wt.) with amphotericin B (1 mg/Kg b.wt.) significantly (p < 0.01) controlled the parasite burden in liver by 96.2% and in spleen by 93.12%. Hence, this study strongly suggested the synergic potential of eugenol oleate with low concentration of amphotericin B in experimental visceral leishmaniasis through anti-leishmanial immune response.


Subject(s)
Amphotericin B/pharmacology , Leishmania donovani/drug effects , Leishmaniasis, Visceral/drug therapy , Macrophages, Peritoneal/drug effects , Trypanocidal Agents/pharmacology , Animals , Cells, Cultured , Cytokines/metabolism , Disease Models, Animal , Drug Synergism , Drug Therapy, Combination , Female , Host-Parasite Interactions , Inflammation Mediators/metabolism , Leishmania donovani/immunology , Leishmania donovani/pathogenicity , Leishmaniasis, Visceral/immunology , Leishmaniasis, Visceral/metabolism , Leishmaniasis, Visceral/parasitology , Liver/drug effects , Liver/immunology , Liver/metabolism , Liver/parasitology , Macrophages, Peritoneal/immunology , Macrophages, Peritoneal/metabolism , Macrophages, Peritoneal/parasitology , Mice, Inbred BALB C , Nitrites/metabolism , Parasite Load , Spleen/drug effects , Spleen/immunology , Spleen/metabolism , Spleen/parasitology , Th1 Cells/drug effects , Th1 Cells/immunology , Th1 Cells/metabolism , Th1 Cells/parasitology , Th1-Th2 Balance , Th2 Cells/drug effects , Th2 Cells/immunology , Th2 Cells/metabolism , Th2 Cells/parasitology
19.
Nat Prod Res ; 35(10): 1644-1647, 2021 May.
Article in English | MEDLINE | ID: mdl-31140307

ABSTRACT

Fractionation of extracts from the culture broth of the marine-derived fungus, Paecilomyces sp. 7A22, resulted in the isolation of the harzialactone A (HA), a known compound previously isolated from fungi of marine environments. The chemical structure of HA was determined by spectroscopic analyses. Upon evaluation of HA on antileishmanial assays against Leishmania amazonensis, HA exhibited significant activity against promastigotes forms with IC50 of 5.25 µg mL-1 and moderate activity against intracellular amastigotes with IC50 of 18.18 µg mL-1. This is the first report on the antileishmanial activity of HA, and the effects of HA presented in this work suggest that this class of compounds are suitable for future biological in vitro and in vivo studies for the search of natural products with activity against Leishmania spp. Furthermore, the present results corroborate marine-derived fungi as a promising source of natural products with antiparasitic activity.


Subject(s)
Antiprotozoal Agents/pharmacology , Lactones/pharmacology , Leishmania mexicana/drug effects , Paecilomyces/chemistry , Animals , Aquatic Organisms , Drug Evaluation, Preclinical/methods , Lactones/chemistry , Lactones/isolation & purification , Leishmaniasis, Cutaneous/drug therapy , Macrophages, Peritoneal/parasitology , Mice, Inbred BALB C , Molecular Structure , Paecilomyces/isolation & purification
20.
Exp Parasitol ; 220: 108044, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33253715

ABSTRACT

Trypanosoma cruzi is the causative agent of Chagas disease, which is endemic in Latin America and around the world through mother to child transmission. The heart is the organ most frequently affected in the chronic stage of the human infection and depends on mitochondria for the required energy for its activity. Cyclophilins are involved in protein folding and the mitochondrial isoform, Cyclophilin D (CyPD), has a crucial role in the opening of the mitochondrial permeability transition pore. In the present study, we infected CyPD deficient mice, with ablation of the Ppif gene, with T. cruzi parasites and the course of the infection was analyzed. Parasite load, quantified by PCR, was significantly lower in skeletal and cardiac tissues of Ppif-/- mice compared to wild type mice. In vitro cultured cardiomyocytes and macrophages from mice lacking CyPD exhibited lower percentage of infected cells and number of intracellular parasites than those observed for wild type mice. Although histopathological analysis of heart and mRNA of heart cytokines showed differences between T. cruzi-infected mice compared to the uninfected animals, no significant differences were found mice due to the ablation of the Ppif gene. Our results suggest that cells deficient for mitochondrial CyPD, inhibited for the mitochondrial membrane potential collapse, reduces the severity of parasite aggression and spread of cellular infection.


Subject(s)
Chagas Disease/parasitology , Peptidyl-Prolyl Isomerase F/deficiency , Trypanosoma cruzi/physiology , Animals , Cytokines/analysis , Cytokines/genetics , DNA, Protozoan/isolation & purification , Heart/parasitology , Liver/pathology , Macrophages, Peritoneal/cytology , Macrophages, Peritoneal/parasitology , Mice , Mice, Inbred C57BL , Muscle, Skeletal/parasitology , Muscle, Skeletal/pathology , Myocardium/pathology , Myocytes, Cardiac/cytology , Myocytes, Cardiac/parasitology , Parasite Load , RNA, Messenger/analysis , RNA, Protozoan/analysis , RNA, Protozoan/isolation & purification , Spleen/pathology , Trypanosoma cruzi/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...